[The value of incretin based therapies].
作者信息
Gallwitz B
机构信息
Medizinische Klinik IV, Universitätsklinikum Tübingen.
出版信息
Dtsch Med Wochenschr. 2009 May;134(20):1062-6. doi: 10.1055/s-0029-1222570. Epub 2009 May 6.
PMID:19421931
Abstract
摘要
相似文献
1
[The value of incretin based therapies].
Dtsch Med Wochenschr. 2009 May;134(20):1062-6. doi: 10.1055/s-0029-1222570. Epub 2009 May 6.
2
[DPP-4 inhibitors in clinical use. Therapy without the risk of hypoglycaemia].
Pharm Unserer Zeit. 2010 Mar;39(2):114-8. doi: 10.1002/pauz.201000358.
3
Choosing among the incretin agents and why it matters.
J Fam Pract. 2010 May;59(5 Suppl):S30-5.
4
[Incretin related agents for treatment of diabetes mellitus].
Nihon Naika Gakkai Zasshi. 2009 Apr 10;98(4):809-16. doi: 10.2169/naika.98.809.
5
Incretin mimetics and dipeptidyl peptidase 4 inhibitors in clinical trials for the treatment of type 2 diabetes.
Expert Opin Investig Drugs. 2008 Jun;17(6):845-53. doi: 10.1517/13543784.17.6.845.
6
[Therapeutic use and adverse events of incretin-related drugs].
Nihon Rinsho. 2012 May;70 Suppl 3:699-702.
7
Distinguishing among incretin-based therapies. Introduction.
J Fam Pract. 2010 Sep;59(9 Suppl 1):S3-4.
8
Incretin-based therapies in type 2 diabetes: a review of clinical results.
Diabetes Res Clin Pract. 2008 Dec 15;82 Suppl 2:S102-7. doi: 10.1016/j.diabres.2008.10.003. Epub 2008 Nov 20.
9
Incretin therapies in the management of elderly patients with type 2 diabetes mellitus.
Hosp Pract (1995). 2011 Feb;39(1):7-21. doi: 10.3810/hp.2011.02.369.
10
Focus on incretin-based therapies: targeting the core defects of type 2 diabetes.
Postgrad Med. 2011 Jan;123(1):53-65. doi: 10.3810/pgm.2011.01.2245.
Zotero 插件